The company says it has identified potent and highly specific INHBE siRNA leads and now expects to select an INHBE clinical candidate in the third quarter of 2024, ahead of expectation. This would enable clinical trial application submission in 2025, Wave said in a statement. Wave also said it plans to deliver proof-of-mechanism data in individuals with AATD in 2024 for WVE-006. Dosing is underway in a potentially registrational FORWARD-53 trial evaluating WVE-N531 in DMD; 24-week data, including dystrophin from muscle biopsies, expected in Q3, the company added. Also, WVE-003 30 mg Q8W multi-dose data with extended follow-up is on track for 2Q 2024; most advanced program designed to lower mutant HTT while also sparing wild-type HTT, Wave said.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on WVE:
- Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Wave Life Sciences upgraded to Outperform from Market Perform at Leerink
- Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
- Wave Life Sciences announces initiation of dosing in Phase 2 FORWARD-53 trial
- Wave Life share raise not understood by market, says Mizuho
